Virus therapy takes on tough cancers in early trial
NCT ID NCT07190833
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing a modified virus called OTS-412, given alone or with hydroxyurea and the immunotherapy atezolizumab, in 27 adults with solid tumors that have stopped responding to standard treatments. The main goal is to check safety and side effects, while also looking at whether the tumors shrink. It is too soon to know if this approach will work, but it may offer a new avenue for patients with few options left.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OTS-412 (a modified vaccinia virus), hydroxyurea, and atezolizumab
What this could lead to
If it works, this could point toward a new treatment option for patients with solid tumors that no longer respond to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 27 participants, so it is primarily testing safety. The virus and drug combination may not shrink tumors or improve survival, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT-REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dong-A University Hospital
RECRUITINGBusan, 49201, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Pusan National University Yangsan Hospital
RECRUITINGBusan, 50612, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••